BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32:720-737. [PMID: 20662774 DOI: 10.1111/j.1365-2036.2010.04406.x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 129] [Article Influence: 13.9] [Reference Citation Analysis]
Number Citing Articles
1 Abdou MM. Synopsis of recent synthetic methods and biological applications of phosphinic acid derivatives. Tetrahedron 2020;76:131251. [DOI: 10.1016/j.tet.2020.131251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kondo T, Miwa H. The Role of Esophageal Hypersensitivity in Functional Heartburn. Journal of Clinical Gastroenterology 2017;51:571-8. [DOI: 10.1097/mcg.0000000000000885] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 2.6] [Reference Citation Analysis]
3 Basnayake C, Geeraerts A, Pauwels A, Koek G, Vaezi M, Vanuytsel T, Tack J. Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment. Aliment Pharmacol Ther 2021;54:755-78. [PMID: 34313333 DOI: 10.1111/apt.16533] [Reference Citation Analysis]
4 Zerbib F, Bredenoord AJ, Fass R, Kahrilas PJ, Roman S, Savarino E, Sifrim D, Vaezi M, Yadlapati R, Gyawali C. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro‐esophageal reflux disease. Neurogastroenterology & Motility 2021;33. [DOI: 10.1111/nmo.14075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Vakil N, Niklasson A, Denison H, Rydén A. Gender differences in symptoms in partial responders to proton pump inhibitors for gastro-oesophageal reflux disease. United European Gastroenterol J 2015;3:443-52. [PMID: 26535123 DOI: 10.1177/2050640614558343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Hendrix I, Page AT, Korhonen MJ, Bell JS, Tan ECK, Visvanathan R, Cooper T, Robson L, Sluggett JK. Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services. Drugs Real World Outcomes 2019;6:105-13. [PMID: 31264165 DOI: 10.1007/s40801-019-0157-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Chandran S, Raman R, Kishor M, Nandeesh HP. The effectiveness of mindfulness meditation in relief of symptoms of depression and quality of life in patients with gastroesophageal reflux disease. Indian J Gastroenterol 2019;38:29-38. [PMID: 30864012 DOI: 10.1007/s12664-019-00940-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
8 Ye B, Wang Y, Lin L, Jiang L, Wang M. Sex-Based Differences in pH Parameters and Esophageal Impedance of Patients With Gastroesophageal Reflux Disease. Front Med (Lausanne) 2021;8:629302. [PMID: 34124085 DOI: 10.3389/fmed.2021.629302] [Reference Citation Analysis]
9 Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-28; quiz 329. [PMID: 23419381 DOI: 10.1038/ajg.2012.444] [Cited by in Crossref: 940] [Cited by in F6Publishing: 680] [Article Influence: 104.4] [Reference Citation Analysis]
10 Talley NJ, Zand Irani M. Optimal management of severe symptomatic gastroesophageal reflux disease. J Intern Med 2021;289:162-78. [PMID: 32691466 DOI: 10.1111/joim.13148] [Reference Citation Analysis]
11 Shaheen NJ, Denison H, Björck K, Karlsson M, Silberg DG. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Gut. 2013;62:1248-1255. [PMID: 22730470 DOI: 10.1136/gutjnl-2012-302737] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
12 Roark R, Sydor M, Chatila AT, Umar S, Guerra R, Bilal M, Guturu P. Management of gastroesophageal reflux disease. Dis Mon 2020;66:100849. [PMID: 30798984 DOI: 10.1016/j.disamonth.2019.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Shinozaki S, Osawa H, Hayashi Y, Miura Y, Lefor AK, Yamamoto H. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep 2021;14:32. [PMID: 33585034 DOI: 10.3892/br.2021.1408] [Reference Citation Analysis]
14 Ekdahl A, Aurell-holmberg A, Castagnoli N. Identification of the metabolites of lesogaberan using linear trap quadrupole orbitrap mass spectrometry and hydrophilic interaction liquid chromatography. Xenobiotica 2012;43:461-7. [DOI: 10.3109/00498254.2012.725486] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
15 Hoppo T, Rodríguez L, Soffer E, Crowell MD, Jobe BA. Long-term results of electrical stimulation of the lower esophageal sphincter for treatment of proximal GERD. Surg Endosc 2014;28:3293-301. [PMID: 25047169 DOI: 10.1007/s00464-014-3603-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
16 Song EJ, Yadlapati R, Chen JW, Parish A, Whitson MJ, Ravi K, Patel A, Carlson DA, Khan A, Niedzwiecki D, Leiman DA. Variability in endoscopic assessment of Nissen fundoplication wrap integrity and hiatus herniation. Dis Esophagus 2021:doab078. [PMID: 34963133 DOI: 10.1093/dote/doab078] [Reference Citation Analysis]
17 Tack J, Becher A, Mulligan C, Johnson DA. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35:1257-1266. [PMID: 22486579 DOI: 10.1111/j.1365-2036.2012.05086.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
18 Boltin D, Boaz M, Aizic S, Sperber A, Fass R, Niv Y, Dickman R. Psychological distress is not associated with treatment failure in patients with gastroesophageal reflux disease. J Psychosom Res 2013;75:462-6. [PMID: 24182636 DOI: 10.1016/j.jpsychores.2013.08.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
19 Boeckxstaens GE, Denison H, Jensen JM, Lehmann A, Ruth M. Translational gastrointestinal pharmacology in the 21st century: ‘the lesogaberan story’. Current Opinion in Pharmacology 2011;11:630-3. [DOI: 10.1016/j.coph.2011.10.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
20 Rodríguez L, Rodriguez P, Gómez B, Ayala JC, Oxenberg D, Perez-Castilla A, Netto MG, Soffer E, Boscardin WJ, Crowell MD. Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease. Surgery. 2015;157:556-567. [PMID: 25726315 DOI: 10.1016/j.surg.2014.10.012] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
21 Jirapinyo P, Thompson CC. Endoscopic gastric plication for the treatment of GERD and underlying class I obesity. VideoGIE 2021;6:74-6. [PMID: 33884332 DOI: 10.1016/j.vgie.2020.10.003] [Reference Citation Analysis]
22 Vakil N, Björck K, Denison H, Halling K, Karlsson M, Paty J, Silberg DG, Rydén A. Validation of the reflux symptom questionnaire electronic diary in partial responders to proton pump inhibitor therapy. Clin Transl Gastroenterol 2012;3:e7. [PMID: 23238029 DOI: 10.1038/ctg.2012.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kumar AR, Katz PO. Commentary: biopsy to diagnose GERD--better, but not yet a stand-alone test. Aliment Pharmacol Ther 2013;38:1139-40. [PMID: 24099476 DOI: 10.1111/apt.12471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Holmberg AA, Ekdahl A, Weidolf L. Systemic Exposure to the Metabolites of Lesogaberan in Humans and Animals: A Case Study of Metabolites in Safety Testing. Drug Metab Dispos 2014;42:1016-21. [DOI: 10.1124/dmd.113.056614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
25 Fan WJ, Hou YT, Sun XH, Li XQ, Wang ZF, Guo M, Zhu LM, Wang N, Yu K, Li JN, Ke MY, Fang XC. Effect of high-fat, standard, and functional food meals on esophageal and gastric pH in patients with gastroesophageal reflux disease and healthy subjects. J Dig Dis 2018;19:664-73. [PMID: 30270576 DOI: 10.1111/1751-2980.12676] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Coyle C, Crawford G, Wilkinson J, Thomas SJ, Bytzer P. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther 2017;45:1524-33. [DOI: 10.1111/apt.14064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
27 Dabrowski A, Štabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR. Prz Gastroenterol. 2018;13:6-15. [PMID: 29657605 DOI: 10.5114/pg.2018.74556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Heading RC, Mönnikes H, Tholen A, Schmitt H. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol. 2011;11:52. [PMID: 21569313 DOI: 10.1186/1471-230X-11-52] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
29 Savarino V, Marabotto E, Zentilin P, Demarzo MG, de Bortoli N, Savarino E. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Des Devel Ther 2021;15:1609-21. [PMID: 33907381 DOI: 10.2147/DDDT.S306371] [Reference Citation Analysis]
30 Fass OZ, Fass R. Overlap Between GERD and Functional Esophageal Disorders—a Pivotal Mechanism for Treatment Failure. Curr Treat Options Gastro 2019;17:161-4. [DOI: 10.1007/s11938-019-00224-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus 2017;30:1-15. [PMID: 28859358 DOI: 10.1093/dote/dox055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
32 Ruiz-Tovar J, Carbajo MA, Jimenez JM, Ortiz-de-Solorzano J, Castro MJ. Gastroesophageal reflux disease in a patient with BMI 30kg/m2 and previous endoscopic vertical gastroplasty: Indication for a one anastomosis gastric bypass. Cir Esp (Engl Ed) 2019;97:416-8. [PMID: 30683273 DOI: 10.1016/j.ciresp.2018.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
33 Kikuchi H, Fukuda S, Koike T, Shimodaira Y, Watanabe K, Saito M, Nakagawa K, Hatta W, Masamune A, Iijima K. Association of residual gastric acid secretion with persistent symptoms in gastroesophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy. Esophagus 2021;18:380-7. [PMID: 32737802 DOI: 10.1007/s10388-020-00765-2] [Reference Citation Analysis]
34 Roman S, Mion F. Refractory GERD, beyond proton pump inhibitors. Curr Opin Pharmacol 2018;43:99-103. [PMID: 30240968 DOI: 10.1016/j.coph.2018.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
35 Asche KU, Kaindlstorfer A, Pointner R. [Surgical and interventional procedures for reflux therapy : Endoscopic or laparoscopic?]. Chirurg 2017;88:188-95. [PMID: 28180974 DOI: 10.1007/s00104-017-0369-4] [Reference Citation Analysis]
36 Ribolsi M, Giordano A, Guarino MPL, Tullio A, Cicala M. New classifications of gastroesophageal reflux disease: an improvement for patient management? Expert Review of Gastroenterology & Hepatology 2019;13:761-9. [DOI: 10.1080/17474124.2019.1645596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Funaki Y, Kaneko H, Kawamura Y, Yoshimine T, Tamura Y, Izawa S, Ebi M, Ogasawara N, Sasaki M, Kasugai K. Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan. Digestion 2017;96:39-45. [PMID: 28641289 DOI: 10.1159/000477801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
38 Soffer E, Rodríguez L, Rodriguez P, Gómez B, Neto MG, Crowell MD. Effect of electrical stimulation of the lower esophageal sphincter in gastroesophageal reflux disease patients refractory to proton pump inhibitors. World J Gastrointest Pharmacol Ther 2016; 7(1): 145-155 [PMID: 26855821 DOI: 10.4292/wjgpt.v7.i1.145] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
39 Han J, Chin M, Fortinsky KJ, Sharaiha R, Gostout CJ, Chang KJ. Endoscopic augmentation of gastroesophageal junction using a full-thickness endoscopic suturing device. Endosc Int Open. 2018;6:E1120-E1125. [PMID: 30211301 DOI: 10.1055/a-0603-3693] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
40 Vakil N, Niklasson A, Denison H, Rydén A. Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations. BMC Gastroenterol 2014;14:177. [PMID: 25304129 DOI: 10.1186/1471-230X-14-177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
41 Van Daele DJ. Esophageal Manometry, pH Testing, Endoscopy, and Videofluoroscopy in Patients With Globus Sensation. The Laryngoscope 2020;130:2120-5. [DOI: 10.1002/lary.28289] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Tielemans MM, van Oijen MG. Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study. BMC Gastroenterol 2013;13:144. [PMID: 24083342 DOI: 10.1186/1471-230X-13-144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Abdou MM, O'Neill PM, Amigues E, Matziari M. Phosphinic acids: current status and potential for drug discovery. Drug Discov Today 2019;24:916-29. [PMID: 30481556 DOI: 10.1016/j.drudis.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
44 Gawron AJ, Rothe J, Fought AJ, Fareeduddin A, Toto E, Boris L, Kahrilas PJ, Pandolfino JE. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10:620-5; quiz e57. [PMID: 22366177 DOI: 10.1016/j.cgh.2012.02.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
45 Faruqui AA. Gastroesophageal Reflux Disease Associated With Anxiety: Efficacy and Safety of Fixed Dose Combination of Amitriptyline and Pantoprazole. Gastroenterology Res 2017;10:301-4. [PMID: 29118871 DOI: 10.14740/gr898e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Miner PB Jr, Silberg DG, Ruth M, Miller F, Pandolfino J. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study. BMC Gastroenterol 2014;14:188. [PMID: 25407279 DOI: 10.1186/1471-230X-14-188] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Rydén A, Leavy OC, Halling K, Stone AA. Comparison of Daily versus Weekly Recording of Gastroesophageal Reflux Disease Symptoms in Patients with a Partial Response to Proton Pump Inhibitor Therapy. Value Health 2016;19:829-33. [PMID: 27712711 DOI: 10.1016/j.jval.2016.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
48 Bonavina L, Fisichella PM, Gavini S, Lee YY, Tatum RP. Clinical course of gastroesophageal reflux disease and impact of treatment in symptomatic young patients. Ann N Y Acad Sci 2020;1481:117-26. [PMID: 32266986 DOI: 10.1111/nyas.14350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
49 Rohof WO, Lei A, Hirsch DP, Ny L, Astrand M, Hansen MB, Boeckxstaens GE. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther. 2012;35:1231-1242. [PMID: 22469098 DOI: 10.1111/j.1365-2036.2012.05081.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
50 Guo MZ, Meng LN. Refractory gastroesophageal reflux disease: Current status and perspectives. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2921-2928 [DOI: 10.11569/wcjd.v25.i33.2921] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Kethman W, Hawn M. New Approaches to Gastroesophageal Reflux Disease. J Gastrointest Surg 2017;21:1544-52. [PMID: 28623447 DOI: 10.1007/s11605-017-3439-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
52 Alecci U, Bonina F, Bonina A, Rizza L, Inferrera S, Mannucci C, Calapai G. Efficacy and Safety of a Natural Remedy for the Treatment of Gastroesophageal Reflux: A Double-Blinded Randomized-Controlled Study. Evid Based Complement Alternat Med 2016;2016:2581461. [PMID: 27818697 DOI: 10.1155/2016/2581461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Huerta-Iga FM, Tamayo-de la Cuesta JL, Noble-Lugo A, Remes-Troche JM, Valdovinos-Díaz MA, Carmona-Sánchez RI; el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico 2011. [The Mexican consensus on gastroesophageal reflux disease. Part I]. Rev Gastroenterol Mex 2012;77:193-213. [PMID: 23153413 DOI: 10.1016/j.rgmx.2012.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Tielemans MM, Jansen JB, van Oijen MG. Open access capture of patients with gastroesophageal reflux disease using an online patient-reported outcomes instrument. Interact J Med Res 2012;1:e7. [PMID: 23611985 DOI: 10.2196/ijmr.2101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
56 Kimura Y, Kamiya T, Senoo K, Tsuchida K, Hirano A, Kojima H, Yamashita H, Yamakawa Y, Nishigaki N, Ozeki T, Endo M, Nakanishi K, Sando M, Inagaki Y, Shikano M, Mizoshita T, Kubota E, Tanida S, Kataoka H, Katsumi K, Joh T. Persistent reflux symptoms cause anxiety, depression, and mental health and sleep disorders in gastroesophageal reflux disease patients. J Clin Biochem Nutr. 2016;59:71-77. [PMID: 27499583 DOI: 10.3164/jcbn.16-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
57 Abdallah J, George N, Yamasaki T, Ganocy S, Fass R. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders. Clin Gastroenterol Hepatol 2019;17:1073-1080.e1. [PMID: 29913281 DOI: 10.1016/j.cgh.2018.06.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
58 Labenz J, Labenz G, Stephan D, Willeke F; LOPA-Studiengruppe. [Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction? MMW Fortschr Med. 2016;158 Suppl 4:7-11. [PMID: 27221555 DOI: 10.1007/s15006-016-8303-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
59 Benedix F, Adolf D, Peglow S, Gstettenbauer LM, Croner R. Short-term outcome after robot-assisted hiatal hernia and anti-reflux surgery-is there a benefit for the patient? Langenbecks Arch Surg 2021;406:1387-95. [PMID: 33409583 DOI: 10.1007/s00423-020-02051-2] [Reference Citation Analysis]
60 Koop H. Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading? Visc Med 2018;34:110-5. [PMID: 29888239 DOI: 10.1159/000486692] [Reference Citation Analysis]
61 Norder Grusell E, Mjörnheim A, Finizia C, Ruth M, Bergquist H. The diagnostic value of GerdQ in subjects with atypical symptoms of gastro-esophageal reflux disease. Scandinavian Journal of Gastroenterology 2018;53:1165-70. [DOI: 10.1080/00365521.2018.1503708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
62 Kim SE, Kim N, Oh S, Kim HM, Park MI, Lee DH, Jung HC. Predictive factors of response to proton pump inhibitors in korean patients with gastroesophageal reflux disease. J Neurogastroenterol Motil 2015;21:69-77. [PMID: 25537676 DOI: 10.5056/jnm14078] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
63 Vaezi MF, Pandolfino JE, Vela MF, Shaheen NJ. White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology 2017;15:1162-72. [DOI: 10.1016/j.cgh.2017.03.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
65 Yadlapati R, Hungness ES, Pandolfino JE. Complications of Antireflux Surgery. Am J Gastroenterol 2018;113:1137-47. [PMID: 29899438 DOI: 10.1038/s41395-018-0115-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
66 Shaheen NJ, Denison H, Björck K, Silberg DG. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy. Am J Gastroenterol 2013;108:529-34. [PMID: 23318482 DOI: 10.1038/ajg.2012.447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
67 Goh KL, Choi MG, Hsu PI, Chun HJ, Mahachai V, Kachintorn U, Leelakusolvong S, Kim N, Rani AA, Wong BC. The Pharmacological and Safety Profile of Dexlansoprazole: a New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region. J Neurogastroenterol Motil. 2016; Mar 1. [Epub ahead of print]. [PMID: 26932927 DOI: 10.5056/jnm15150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
68 Guadagnoli L, Simons M, Mcgarva J, Taft TH, van Tilburg MA. Improving Patient Adherence to Lifestyle Changes for the Management of Gastroesophageal Reflux. PPA 2022;Volume 16:897-909. [DOI: 10.2147/ppa.s356466] [Reference Citation Analysis]
69 Nandwani M, Clarke JO, Kuriakose C, Stevenson E. Impact of nurse practitioner navigation on access to care for patients with refractory gastroesophageal reflux disease. J Am Assoc Nurse Pract 2021;33:77-85. [PMID: 31567776 DOI: 10.1097/JXX.0000000000000296] [Reference Citation Analysis]
70 Peura DA, Pilmer B, Hunt B, Mody R, Perez MC. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38:1303-1311. [PMID: 24118079 DOI: 10.1111/apt.12504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
71 Rydén A, Martin M, Halling K, Niklasson A. Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study. Patient. 2013;6:307-314. [PMID: 23990378 DOI: 10.1007/s40271-013-0024-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
72 Kappelle WFW, Bredenoord AJ, Conchillo JM, Ruurda JP, Bouvy ND, van Berge Henegouwen MI, Chiu PW, Booth M, Hani A, Reddy DN, Bogte A, Smout AJPM, Wu JC, Escalona A, Valdovinos MA, Torres-villalobos G, Siersema PD. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial. Aliment Pharmacol Ther 2015;42:614-25. [DOI: 10.1111/apt.13306] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
73 Taft TH, Guadagnoli L, Carlson DA, Kou W, Keefer L, Pandolfino J. Validation of the Short-Form Esophageal Hypervigilance and Anxiety Scale. Clin Gastroenterol Hepatol 2021:S1542-3565(20)31716-X. [PMID: 33348046 DOI: 10.1016/j.cgh.2020.12.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther 2021;54:129-43. [PMID: 34114655 DOI: 10.1111/apt.16407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
75 Devault KR. Refractory regurgitation responds to magnetic sphincter augmentation but not to increased proton pump inhibitor dose. Gastrointestinal Endoscopy 2019;89:23-4. [DOI: 10.1016/j.gie.2018.10.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
76 Farmer AD, Albusoda A, Amarasinghe G, Ruffle JK, Fitzke HE, Idrees R, Fried R, Brock C, Aziz Q. Transcutaneous vagus nerve stimulation prevents the development of, and reverses, established oesophageal pain hypersensitivity. Aliment Pharmacol Ther 2020;52:988-96. [PMID: 32767824 DOI: 10.1111/apt.15869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Andrae DA, Hanlon J, Cala ML, Scippa K, Graham C, Witherspoon B, Shao JZ, Reasner D. Evaluation and Validation of the Modified Reflux Symptom Questionnaire-Electronic Diary in Patients With Persistent Gastroesophageal Reflux Disease. Clin Transl Gastroenterol 2020;11:e00117. [PMID: 31977454 DOI: 10.14309/ctg.0000000000000117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Loo GH, Rajan R, Deva Tata M, Ritza Kosai N. Changes in the disease-specific quality of life following Dor fundoplication. A multicentre cross-sectional study. Ann Med Surg (Lond) 2020;55:252-5. [PMID: 32528674 DOI: 10.1016/j.amsu.2020.05.018] [Reference Citation Analysis]
79 Hussain ZH, Henderson EE, Maradey-Romerao C, George N, Fass R, Lacy BE. The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum. Clin Transl Gastroenterol. 2015;6:e106. [PMID: 26270485 DOI: 10.1038/ctg.2015.32] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
80 Gyawali CP, Azagury DE, Chan WW, Chandramohan SM, Clarke JO, Bortoli N, Figueredo E, Fox M, Jodorkovsky D, Lazarescu A, Malfertheiner P, Martinek J, Murayama KM, Penagini R, Savarino E, Shetler KP, Stein E, Tatum RP, Wu J. Nonerosive reflux disease: clinical concepts. Ann N Y Acad Sci 2018;1434:290-303. [DOI: 10.1111/nyas.13845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
81 Taft TH, Triggs JR, Carlson DA, Guadagnoli L, Tomasino KN, Keefer L, Pandolfino JE. Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease. Aliment Pharmacol Ther 2018;47:1270-7. [PMID: 29528128 DOI: 10.1111/apt.14605] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
82 Portnoy JE, Gregory ND, Cerulli CE, Hawkshaw MJ, Lurie D, Katz PO, Sataloff RT. Efficacy of super high dose proton pump inhibitor administration in refractory laryngopharyngeal reflux: a pilot study. J Voice. 2014;28:369-377. [PMID: 24495427 DOI: 10.1016/j.jvoice.2013.10.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
83 Reimer C, Lødrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther 2016;43:899-909. [DOI: 10.1111/apt.13567] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
84 Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 2018; 24(14): 1550-1561 [PMID: 29662293 DOI: 10.3748/wjg.v24.i14.1550] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
85 Joo YH, Song YS, Pae CU. Relationship between Depression and Laryngopharyngeal Reflux. Psychiatry Investig 2017;14:226-9. [PMID: 28326123 DOI: 10.4306/pi.2017.14.2.226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
86 Reavis KM, Perry KA. Transoral incisionless fundoplication for the treatment of gastroesophageal reflux disease. Expert Rev Med Devices 2014;11:341-50. [PMID: 24918903 DOI: 10.1586/17434440.2014.925394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Triadafilopoulos G, Clarke JO, Hawn M. Precision GERD management for the 21st century. Diseases of the Esophagus 2017;30:1-6. [DOI: 10.1093/dote/dox079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
88 Jaruvongvanich V, Matar RH, Movitz BR, Ravi K, Chesta F, Maselli DB, Mckenzie TJ, Kellogg TA, Kendrick ML, Abu Dayyeh BK. Long-term outcomes of Roux-en-Y gastric diversion after failed surgical fundoplication in a large cohort and a systematic review. Surgery for Obesity and Related Diseases 2021;17:161-9. [DOI: 10.1016/j.soard.2020.08.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Kim YS, Kim N, Kim GH. Sex and Gender Differences in Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2016;22:575-588. [PMID: 27703114 DOI: 10.5056/jnm16138] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 9.5] [Reference Citation Analysis]
90 Kahrilas PJ, Jonsson A, Denison H, Wernersson B, Hughes N, Howden CW. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy. Gut. 2014;63:720-726. [PMID: 23831734 DOI: 10.1136/gutjnl-2013-304883] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
91 Stålhammar NO, Spiegel BM, Granstedt Löfman H, Karlsson M, Wahlqvist P, Næsdal J, Nelson MT, Despiégel N. Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA. Pragmat Obs Res 2012;3:57-67. [PMID: 27774018 DOI: 10.2147/POR.S36704] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
92 Pierce D, Corcoran M, Velinova M, Hossack S, Hoppenbrouwers M, Martin P. A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. Drug Des Devel Ther 2015;9:1257-68. [PMID: 25767373 DOI: 10.2147/DDDT.S64621] [Reference Citation Analysis]
93 Ruigómez A, Johansson S, Wernersson B, Fernández Cantero O, García Rodríguez LA. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012;47:751-761. [PMID: 22519917 DOI: 10.3109/00365521.2012.679682] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
94 Sterris JA, Dunn CP, Bildzukewicz NA, Lipham JC. Magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: pros and cons. Curr Opin Gastroenterol 2020;36:323-8. [PMID: 32398565 DOI: 10.1097/MOG.0000000000000643] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Sierra-Arango F, Castaño DM, Forero JD, Pérez-Riveros ED, Ardila Duarte G, Botero ML, Cárdenas A, De la Hoz-Valle J. A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease. Can J Gastroenterol Hepatol 2019;2019:3926051. [PMID: 31929980 DOI: 10.1155/2019/3926051] [Reference Citation Analysis]
96 Pandolfino J, Lipham J, Chawla A, Ferko N, Hogan A, Qadeer RA. A budget impact analysis of a magnetic sphincter augmentation device for the treatment of medication-refractory mechanical gastroesophageal reflux disease: a United States payer perspective. Surg Endosc 2020;34:1561-72. [PMID: 31559575 DOI: 10.1007/s00464-019-06916-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Fass R. Editorial: Healing Erosive Esophagitis With a Proton Pump Inhibitor: The More the Merrier? American Journal of Gastroenterology 2012;107:531-3. [DOI: 10.1038/ajg.2012.25] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
98 Jobe BA, Richter JE, Hoppo T, Peters JH, Bell R, Dengler WC, DeVault K, Fass R, Gyawali CP, Kahrilas PJ, Lacy BE, Pandolfino JE, Patti MG, Swanstrom LL, Kurian AA, Vela MF, Vaezi M, DeMeester TR. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. J Am Coll Surg. 2013;217:586-597. [PMID: 23973101 DOI: 10.1016/j.jamcollsurg.2013.05.023] [Cited by in Crossref: 142] [Cited by in F6Publishing: 79] [Article Influence: 15.8] [Reference Citation Analysis]
99 Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2021. [PMID: 34807007 DOI: 10.14309/ajg.0000000000001538] [Reference Citation Analysis]
100 Kim SE, Soffer E. Electrical stimulation for gastroesophageal reflux disease: current state of the art. Clin Exp Gastroenterol. 2016;9:11-19. [PMID: 26834494 DOI: 10.2147/ceg.s84016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
101 Fuller G, Bolus R, Whitman C, Talley J, Erder MH, Joseph A, Silberg DG, Spiegel B. PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux Disease. Dig Dis Sci 2017;62:593-606. [DOI: 10.1007/s10620-016-4440-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
102 Trad KS, Barnes WE, Simoni G, Shughoury AB, Mavrelis PG, Raza M, Heise JA, Turgeon DG, Fox MA. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial. Surg Innov. 2015;22:26-40. [PMID: 24756976 DOI: 10.1177/1553350614526788] [Cited by in Crossref: 76] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
103 Dunn C, Bildzukewicz N, Lipham J. Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease. Gastrointest Endosc Clin N Am 2020;30:325-42. [PMID: 32146949 DOI: 10.1016/j.giec.2019.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Koufman JA. Low-Acid Diet for Recalcitrant Laryngopharyngeal Reflux: Therapeutic Benefits and Their Implications. Ann Otol Rhinol Laryngol 2011;120:281-7. [DOI: 10.1177/000348941112000501] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
105 Tatarian T, Pucci MJ, Palazzo F. A Modern Approach to the Surgical Treatment of Gastroesophageal Reflux Disease. Journal of Laparoendoscopic & Advanced Surgical Techniques 2016;26:174-9. [DOI: 10.1089/lap.2015.0530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34:618-627. [PMID: 21770991 DOI: 10.1111/j.1365-2036.2011.04774.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
107 Lin D, Triadafilopoulos G. Dual Ambulatory pH Monitoring in Patients with Gastroesophageal Reflux Rendered Asymptomatic with Proton Pump Inhibitor Therapy. Dig Dis Sci 2015;60:1343-9. [PMID: 25135815 DOI: 10.1007/s10620-014-3324-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
108 Kahrilas PJ, Savarino E, Anastasiou F, Bredenoord AJ, Corsetti M, Lagergren J, Mendive J, Nelson S, Roman S, Zerbib F, Hungin P. The tapestry of reflux syndromes: translating new insight into clinical practice. Br J Gen Pract 2021;71:470-3. [PMID: 34593403 DOI: 10.3399/bjgp21X717329] [Reference Citation Analysis]
109 Zerbib F, Sacher-Huvelin S, Coron E, Coffin B, Melchior C, Ponchon T, Cholet F, Chabrun E, Vavasseur F, Gorbatchef C, Zalar A, Mion F, Robaszkiewicz M, Le Rhun M, Leroy M, Paul Galmiche J, Bruley des Varannes S. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn. Aliment Pharmacol Ther 2020;52:637-45. [PMID: 32656869 DOI: 10.1111/apt.15936] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
110 Koufman JA, Johnston N. Potential benefits of pH 8.8 alkaline drinking water as an adjunct in the treatment of reflux disease. Ann Otol Rhinol Laryngol 2012;121:431-4. [PMID: 22844861 DOI: 10.1177/000348941212100702] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
111 Roman S, Keefer L, Imam H, Korrapati P, Mogni B, Eident K, Friesen L, Kahrilas PJ, Martinovich Z, Pandolfino JE. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux. Neurogastroenterol Motil 2015;27:1667-74. [PMID: 26337396 DOI: 10.1111/nmo.12666] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
112 Han X, Zhang Y, Lee A, Li Z, Gao J, Wu X, Zhao J, Wang H, Chen D, Zou D, Owyang C. Upregulation of acid sensing ion channels is associated with esophageal hypersensitivity in GERD. FASEB J 2022;36:e22083. [PMID: 34918385 DOI: 10.1096/fj.202100606R] [Reference Citation Analysis]
113 Aggarwal P, Kamal AN. Reflux Hypersensitivity: How to Approach Diagnosis and Management. Curr Gastroenterol Rep 2020;22:42. [PMID: 32651667 DOI: 10.1007/s11894-020-00779-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Hillman L, Yadlapati R, Whitsett M, Thuluvath AJ, Berendsen MA, Pandolfino JE. Review of antireflux procedures for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus 2017;30:1-14. [PMID: 28859357 DOI: 10.1093/dote/dox054] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
115 Park I, Kang J, Seo J, Hwang S, Youn H, Jin H, Kang H, Joo Y. Analysis of Relationship between Reflux Symptom Index and Psychiatric Problems. Korean J Otorhinolaryngol-Head Neck Surg 2018;61:692-6. [DOI: 10.3342/kjorl-hns.2017.00738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Rydholm H, von Corswant C, Denison H, Jensen JM, Lehmann A, Ruth M, Söderlind E, Aurell-Holmberg A. Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia. Clin Ther 2016;38:946-60. [PMID: 26947796 DOI: 10.1016/j.clinthera.2016.02.012] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
117 Hamdy E, El Nakeeb A, Hamed H, El Hemaly M, ElHak NG. Outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease in non-responders to proton pump inhibitors. J Gastrointest Surg. 2014;18:1557-1562. [PMID: 24985244 DOI: 10.1007/s11605-014-2584-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
118 Park S, Park S, Park JM, Ryu S, Hwang J, Kwon JW, Seo KW. Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea. J Neurogastroenterol Motil 2020;26:215-23. [PMID: 32235028 DOI: 10.5056/jnm19188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
119 Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology 2020;158:1250-1261.e2. [PMID: 31866243 DOI: 10.1053/j.gastro.2019.12.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 10.3] [Reference Citation Analysis]
120 Asaoka D, Nagahara A, Hojo M, Matsumoto K, Ueyama H, Matsumoto K, Izumi K, Takeda T, Komori H, Akazawa Y, Shimada Y, Osada T, Watanabe S. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep 2017;6:175-80. [PMID: 28357069 DOI: 10.3892/br.2016.828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
121 Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419-1425; quiz 1426. [PMID: 21537361 DOI: 10.1038/ajg.2011.146] [Cited by in Crossref: 103] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
122 Ohmure H, Kanematsu-hashimoto K, Nagayama K, Taguchi H, Ido A, Tominaga K, Arakawa T, Miyawaki S. Evaluation of a Proton Pump Inhibitor for Sleep Bruxism: A Randomized Clinical Trial. J Dent Res 2016;95:1479-86. [DOI: 10.1177/0022034516662245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
123 Maev IV, Andreev DN, Kucheryavyy YA, Shaburov RI. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii arkhiv 2019;91:4-11. [DOI: 10.26442/00403660.2019.08.000387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Vaezi MF, Fass R, Vakil N, Reasner DS, Mittleman RS, Hall M, Shao JZ, Chen Y, Lane L, Gates AM, Currie MG. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology 2020;158:2093-103. [DOI: 10.1053/j.gastro.2020.02.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
125 Lee J, Youn K, Choi N, Lee J, Kang D, Song H, Park B. A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013;48:1016-22. [DOI: 10.1007/s00535-012-0722-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
126 Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. Lancet. 2013;381:1933-1942. [PMID: 23477993 DOI: 10.1016/s0140-6736(12)62171-0] [Cited by in Crossref: 93] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
127 Bor S, Kalkan İH, Çelebi A, Dinçer D, Akyüz F, Dettmar P, Özen H. Alginates: From the ocean to gastroesophageal reflux disease treatment. Turk J Gastroenterol 2019;30:109-36. [PMID: 31624050 DOI: 10.5152/tjg.2019.19677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
128 Labenz J. [Conservative Therapy of Reflux Disease and its Limits]. Zentralbl Chir 2021;146:176-87. [PMID: 33598907 DOI: 10.1055/a-1309-2368] [Reference Citation Analysis]
129 Malfa GA, Di Giacomo C, Cardia L, Sorbara EE, Mannucci C, Calapai G. A standardized extract of Opuntia ficus‐indica (L.) Mill and Olea europaea L. improves gastrointestinal discomfort: A double‐blinded randomized‐controlled study. Phytotherapy Research 2021;35:3756-68. [DOI: 10.1002/ptr.7074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Rydén A, Denison H, Karlsson M, Vakil N. Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. Scand J Gastroenterol 2013;48:1018-26. [PMID: 23919738 DOI: 10.3109/00365521.2013.822544] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
131 Riva CG, Asti E, Lazzari V, Aquilino K, Siboni S, Bonavina L. Magnetic Sphincter Augmentation After Gastric Surgery. JSLS 2019;23:e2019. [PMID: 31624454 DOI: 10.4293/JSLS.2019.00035] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
132 Fock KM, Talley N, Goh KL, Sugano K, Katelaris P, Holtmann G, Pandolfino JE, Sharma P, Ang TL, Hongo M, Wu J, Chen M, Choi MG, Law NM, Sheu BS, Zhang J, Ho KY, Sollano J, Rani AA, Kositchaiwat C, Bhatia S. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut. 2016;65:1402-1415. [PMID: 27261337 DOI: 10.1136/gutjnl-2016-311715] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
133 Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 2021;22:219-27. [PMID: 32893683 DOI: 10.1080/14656566.2020.1817385] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Paterson AL, Lao-Sirieix P, O'Donovan M, Debiram-Beecham I, di Pietro M, Miremadi A, Attwood SE, Walter FM, Sasieni PD, Fitzgerald RC; BEST and BEST2 study groups. Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. Histopathology 2017;70:203-10. [PMID: 27417524 DOI: 10.1111/his.13039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
135 Chiu J, Soffer E. Novel surgical options for gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2015;9:943-51. [PMID: 25947638 DOI: 10.1586/17474124.2015.1039986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
136 Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154:302-318. [PMID: 28827081 DOI: 10.1053/j.gastro.2017.07.049] [Cited by in Crossref: 109] [Cited by in F6Publishing: 75] [Article Influence: 21.8] [Reference Citation Analysis]
137 Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635-643. [PMID: 22860764 DOI: 10.1111/apt.12007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
138 Xu LY, Yu BY, Cen LS. New treatment for gastroesophageal reflux disease: Traditional Chinese medicine Xiaochaihu decoction. World J Gastroenterol 2022; 28(11): 1184-1186 [DOI: 10.3748/wjg.v28.i11.1184] [Reference Citation Analysis]
139 Heading RC. Proton pump inhibitor failure in gastro-oesophageal reflux disease: a perspective aided by the Gartner hype cycle. Clin Med (Lond) 2017;17:132-6. [PMID: 28365622 DOI: 10.7861/clinmedicine.17-2-132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
140 Kwak YE, Saleh A, Abdelwahed A, Sanchez M, Masoud A. Effectiveness of esophagogastroduodenoscopy in changing treatment outcome in refractory gastro-esophageal reflux disease. Scand J Gastroenterol 2021;:1-7. [PMID: 34669534 DOI: 10.1080/00365521.2021.1988141] [Reference Citation Analysis]
141 Park S, Kwon JW, Park JM, Park S, Seo KW. Treatment Pattern and Economic Burden of Refractory Gastroesophageal Reflux Disease Patients in Korea. J Neurogastroenterol Motil 2020;26:281-8. [PMID: 31682754 DOI: 10.5056/jnm19050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
142 Han G, Leem J, Lee H, Lee J. Electroacupuncture to treat gastroesophageal reflux disease: study protocol for a randomized controlled trial. Trials 2016;17:246. [PMID: 27188910 DOI: 10.1186/s13063-016-1371-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
143 Goh KL, Choi KD, Choi MG, Hsieh TY, Jung HY, Lien HC, Menon J, Mesenas S, Park H, Sheu BS, Wu JC. Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients. BMC Gastroenterol 2014;14:156. [PMID: 25200403 DOI: 10.1186/1471-230X-14-156] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
144 Bonavina L, Attwood S. Laparoscopic alternatives to fundoplication for gastroesophageal reflux: the role of magnetic augmentation and electrical stimulation of the lower esophageal sphincter. Dis Esophagus 2016;29:996-1001. [PMID: 26676715 DOI: 10.1111/dote.12425] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
145 Bruley des Varannes S, Löfman HG, Karlsson M, Wahlqvist P, Ruth M, Furstnau ML, Despiégel N, Stålhammar NO. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France. BMC Gastroenterol. 2013;13:39. [PMID: 23448382 DOI: 10.1186/1471-230X-13-39] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
146 Guadagnoli L, Yadlapati R, Taft T, Pandolfino JE, Tye M, Keefer L. Esophageal hypervigilance is prevalent across gastroesophageal reflux disease presentations. Neurogastroenterol Motil 2021;33:e14081. [PMID: 33432708 DOI: 10.1111/nmo.14081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
147 Jung HK, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, Shin JE, Lim HC, Lee SK, Jung DH, Choi YJ, Seo SI, Kim JS, Lee JM, Kim BJ, Kang SH, Park CH, Choi SC, Kwon JG, Park KS, Park MI, Lee TH, Kim SY, Cho YS, Lee HH, Jung KW, Kim DH, Moon HS, Miwa H, Chen CL, Gonlachanvit S, Ghoshal UC, Wu JCY, Siah KTH, Hou X, Oshima T, Choi MY, Lee KJ; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:453-81. [PMID: 34642267 DOI: 10.5056/jnm21077] [Reference Citation Analysis]
148 Niu XP, Yu BP, Wang YD, Han Z, Liu SF, He CY, Zhang GZ, Wu WC. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol 2013; 19(20): 3124-3129 [PMID: 23716993 DOI: 10.3748/wjg.v19.i20.3124] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]